A new study published in the journal Psychopharmacology is presenting a comprehensive look at the long-term efficacy of MDMA-assisted psychotherapy for the treatment of post-traumatic stress disorder (PTSD). The study finds not only do the substantial beneficial effects of the therapy hold strong for well over a year after completing the treatment, but patients continue to improve as time passes following the few MDMA sessions.
After decades of prohibition and stigma, MDMA is finally on the precipice of becoming a clinically approved medicine. Currently deep in Phase 3 human trials for severe treatment-resistant PTSD, the therapy has proved so effective the U.S. Food and Drug Administration (FDA) recently approved it for Expanded Access, a program allowing certain patients access to the therapy before full market approval is granted.
Read from original article